{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:50:05Z","timestamp":1785894605506,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005064","name":"Hebei Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["21372410D"],"award-info":[{"award-number":["21372410D"]}],"id":[{"id":"10.13039\/501100005064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.05.045","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:33:29Z","timestamp":1780328009000},"page":"956.e1-956.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"given":"Xing-yu","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-7369","authenticated-orcid":false,"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.045_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106627","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia\/lymphoma: a single-center study","author":"Yasuda","year":"2021","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.045_bib0002","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s00277-024-05716-w","article-title":"Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia\/lymphoma in first complete remission: a single-center study","volume":"1037","author":"Gu","year":"2024","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.045_bib0003","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41409-023-01989-3","article-title":"Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"588","author":"Gao","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.045_bib0004","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the acute leukemia working party of EBMT","volume":"266","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.045_bib0005","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"9812","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.045_bib0006","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"1404","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.jtct.2026.05.045_bib0007","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"3930","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.045_bib0008","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"311","author":"Pan","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.045_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13045-023-01427-3","article-title":"Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia","volume":"161","author":"Tan","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.045_bib0010","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3324\/haematol.2023.283848","article-title":"Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia","volume":"1096","author":"Oh","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.045_bib0011","article-title":"Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.045_bib0012","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"125","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"146","key":"10.1016\/j.jtct.2026.05.045_bib0013","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.2025029299","article-title":"Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial","volume":"23146","author":"Pan","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.045_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70081","article-title":"Clinical outcomes of CD7 CAR-T cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma patients","volume":"433","author":"Xiao","year":"2025","journal-title":"Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.045_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia","volume":"3942","author":"Chiesa","year":"2026","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.045_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"254","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Tr"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.045_bib0017","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"156","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.045_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium","volume":"221","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Tr"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.045_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"213","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Tr"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.045_bib0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"1068","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.045_bib0021","first-page":"151","volume":"293","author":"Schoettler","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.045_bib0022","first-page":"359","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews","volume":"206","author":"Cappell","year":"2023","journal-title":"Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.045_bib0023","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"1283","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jtct.2026.05.045_bib0024","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.3390\/cancers13184664","article-title":"CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies?","volume":"1318","author":"Bartol\u00f3-Ibars","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.045_bib0025","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.1500117","article-title":"Cytokines in graft-versus-host disease","volume":"19410","author":"Henden","year":"2015","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.045_bib0026","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"12710","author":"Jacoby","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.045_bib0027","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","article-title":"How risky is a second allogeneic stem cell transplantation?","volume":"388","author":"Penack","year":"2024","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.045_bib0028","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1111\/bjh.19445","volume":"2046","author":"Cao","year":"2024","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.jtct.2026.05.045_bib0029","article-title":"Analysis benefits of a second allo-HSCT after CAR-T cell therapy in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.05.045_bib0030","article-title":"Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: a single center study","author":"Lu","year":"2023","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.045_bib0031","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"415","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.045_bib0032","article-title":"Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.045_bib0033","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcyt.2024.04.075","article-title":"Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors","volume":"269","author":"Miller","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.05.045_bib0034","article-title":"Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up","author":"Li","year":"2024","journal-title":"Front Immunol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:21:45Z","timestamp":1785892905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726004458"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.045","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}